Vaccine Market Analysis By Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines), By Application (Infectious Diseases, Cancer, Autism, Allergy) And Segment Forecasts to 2024
The global vaccine market is expected to reach over USD 77.5 billion by 2024, according to a new report by Grand View Research, Inc. The presence of numerous molecules in the pipeline is anticipated to meet the demand for efficient vaccines. These include vaccines for chest infection, tuberculosis, malaria, and dengue. Most of the key players are actively leveraging on their vaccine development technologies to launch novel preventative solutions with an objective to increase their market share. For instance, Pfizer, Inc. is involved in the development of vaccines to prevent severe infections caused by Meningococcal B, Clostridium difficile, and Staphylococcus aureus.
Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.
For instance, the ‘Immunize Australia Program’ sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases. Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.
Further key findings from the study suggest:
The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines. In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.
The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area. Other advantages associated are ease of production, long lasting immunogenicity, and no risk of reversion.
The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.
North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region
Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India. Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.
Leading players in this industry, among others are, Merck & Co., Inc., Emergent BioSolutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., and GlaxoSmithKline Plc. Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.
In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its “Lipid Particle Vaccine” formulation technology to better the stability of the Sanofi vaccines.
Furthermore, the broad coalition of governments, worldwide, working to promote the awareness of vaccination benefits through immunization programs with the objective of containing the propagation of communicable diseases that are associated with high morbidity and mortality is expected to stimulate the market growth.
For instance, the ‘Immunize Australia Program’ sponsors the immunization of individuals, which acts as a preventative action in preventing disease occurrence and checks rampant disease transmission thus protecting millions of Australians from severe diseases. Another program that has been involved in achieving extensive immunization coverage on the Indian continent is the National Immunization Program, a government program that has focused on taking strong preventive measures to offset vaccine-preventable diseases, particularly in children.
Further key findings from the study suggest:
The inactivated vaccine type segment was estimated to have over 14.5% market share in 2015 owing to the related advantages including easy storage and transport due to the highly stable nature of these vaccines. In December 2015, Sanofi Pasteur, Inc. launched a new trivalent, inactivated polio vaccine in India.
The DNA vaccine segment is presumed to be the fastest growing type over the forecast period owing to the ease of production compared to the cell-based vaccines and the promising, targeted immunization outcomes coupled with the continual developments in the biotechnology area. Other advantages associated are ease of production, long lasting immunogenicity, and no risk of reversion.
The cancer application segment is expected to witness the fastest growth with a CAGR of over 11.8% in the vaccinations market majorly attributable to the need for immunization against cancer coupled with the increasing prevalence of various types of cancer, such as cervical and colorectal cancers.
North America dominated the market in terms of revenue with over USD 12 billion in 2015, due mainly to the presence of extensive research and development activities and the existence of key participants of the industry in this region
Asia Pacific is identified to witness a lucrative growth with a CAGR of around 10.7% during the forecast period due to the growing population base and the increasing economic growth of countries, such as China, Japan, and India. Moreover, the availability of skilled labors at a lower cost and the low manufacturing operations cost provide a platform for clinical trial outsourcing of the vaccinations under development to expedite commercialization.
Leading players in this industry, among others are, Merck & Co., Inc., Emergent BioSolutions, Inc., Johnson and Johnson, Sanofi Pasteur, Inc., Pfizer, Inc., Novartis AG, CSL Ltd., and GlaxoSmithKline Plc. Other prominent players include Abbott Laboratories, Inc., AstraZeneca plc, Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals International, Inc.
In April 2016, VBI vaccines, Inc. entered into a collaborative agreement with Sanofi Pasteur, Inc. to employ its “Lipid Particle Vaccine” formulation technology to better the stability of the Sanofi vaccines.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 Company Market Share Analysis : Methodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS & SCOPE
4.1 Market segmentation & scope
4.2 Market size and growth prospects
4.2.1 Market Driver Analysis
4.2.1.1 Rise in importance of immunization across the globe
4.2.1.2 High predominance of chronic diseases
4.2.1.3 Technology advancements in the types of vaccines
4.2.1.4 Other drivers
4.2.2 Market Restraint Analysis
4.2.2.1 Cost of immunization
4.2.2.2 Lack of healthcare infrastructure
4.3 Penetration & growth prospect mapping
4.4 Vaccines - SWOT Analysis, By Factor (political & legal, economic and technological)
4.5 Industry Analysis - Porter’s
4.6 Vaccines company market share/competitive landscape, 2015
CHAPTER 5 MARKET CATEGORIZATION 1: VACCINES TYPE ESTIMATES & TREND ANALYSIS
5.1 Vaccine Market: Vaccine type movement analysis
5.2 Live attenuated vaccines
5.2.1 Live attenuated Vaccine Market, 2013 - 2024 (USD Million)
5.3 Inactivated vaccines
5.3.1 Inactivated Vaccine Market, 2013 - 2024 (USD Million)
5.4 Subunit vaccines
5.4.1 Subunit Vaccine Market, 2013 - 2024 (USD Million)
5.5 Toxoid vaccines
5.5.1 Toxoid Vaccine Market, 2013 - 2024 (USD Million)
5.6 Conjugate vaccines
5.6.1 Conjugate Vaccine Market, 2013 - 2024 (USD Million)
5.7 DNA vaccines
5.7.1 DNA Vaccine Market, 2013 - 2024 (USD Million)
5.8 Others
5.8.1 Other Vaccine Market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: VACCINE APPLICATION ESTIMATES & TREND ANALYSIS
6.1 Vaccine Market: Application movement analysis
6.2 Infectious Diseases
6.2.1 Infectious Diseases market, 2013 - 2024 (USD Million)
6.3 Cancer
6.3.1 Cancer market, 2013 - 2024 (USD Million)
6.4 Autism
6.4.1 Autism market, 2013 - 2024 (USD Million)
6.5 Allergy
6.5.1 Allergy market, 2013 - 2024 (USD Million)
6.6 Others
6.6.1 Other applications market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY TYPE & APPLICATION
7.1 Vaccine Market share by region, 2015 & 2024
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.5 Latin America
7.5.1 Brazil
7.6 MEA
7.6.1 South Africa
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Merck & Co. Inc
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 GlaxoSmithKline plc (GSK)
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 SANOFI S.A
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Pfizer Inc.
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 NOVARTIS AG
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Takeda Pharmaceuticals
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Astellas Pharma Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Emergent BioSolutions
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 AstraZeneca
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Mitsubishi Tanabe
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 Company Market Share Analysis : Methodology
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET SNAPSHOT
CHAPTER 4 MARKET VARIABLES, TRENDS & SCOPE
4.1 Market segmentation & scope
4.2 Market size and growth prospects
4.2.1 Market Driver Analysis
4.2.1.1 Rise in importance of immunization across the globe
4.2.1.2 High predominance of chronic diseases
4.2.1.3 Technology advancements in the types of vaccines
4.2.1.4 Other drivers
4.2.2 Market Restraint Analysis
4.2.2.1 Cost of immunization
4.2.2.2 Lack of healthcare infrastructure
4.3 Penetration & growth prospect mapping
4.4 Vaccines - SWOT Analysis, By Factor (political & legal, economic and technological)
4.5 Industry Analysis - Porter’s
4.6 Vaccines company market share/competitive landscape, 2015
CHAPTER 5 MARKET CATEGORIZATION 1: VACCINES TYPE ESTIMATES & TREND ANALYSIS
5.1 Vaccine Market: Vaccine type movement analysis
5.2 Live attenuated vaccines
5.2.1 Live attenuated Vaccine Market, 2013 - 2024 (USD Million)
5.3 Inactivated vaccines
5.3.1 Inactivated Vaccine Market, 2013 - 2024 (USD Million)
5.4 Subunit vaccines
5.4.1 Subunit Vaccine Market, 2013 - 2024 (USD Million)
5.5 Toxoid vaccines
5.5.1 Toxoid Vaccine Market, 2013 - 2024 (USD Million)
5.6 Conjugate vaccines
5.6.1 Conjugate Vaccine Market, 2013 - 2024 (USD Million)
5.7 DNA vaccines
5.7.1 DNA Vaccine Market, 2013 - 2024 (USD Million)
5.8 Others
5.8.1 Other Vaccine Market, 2013 - 2024 (USD Million)
CHAPTER 6 MARKET CATEGORIZATION 2: VACCINE APPLICATION ESTIMATES & TREND ANALYSIS
6.1 Vaccine Market: Application movement analysis
6.2 Infectious Diseases
6.2.1 Infectious Diseases market, 2013 - 2024 (USD Million)
6.3 Cancer
6.3.1 Cancer market, 2013 - 2024 (USD Million)
6.4 Autism
6.4.1 Autism market, 2013 - 2024 (USD Million)
6.5 Allergy
6.5.1 Allergy market, 2013 - 2024 (USD Million)
6.6 Others
6.6.1 Other applications market, 2013 - 2024 (USD Million)
CHAPTER 7 MARKET CATEGORIZATION 3: REGIONAL ESTIMATES & TREND ANALYSIS, BY TYPE & APPLICATION
7.1 Vaccine Market share by region, 2015 & 2024
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.5 Latin America
7.5.1 Brazil
7.6 MEA
7.6.1 South Africa
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 Strategy framework
8.2 Market participation categorization
8.3 Company Profiles
8.3.1 Merck & Co. Inc
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 GlaxoSmithKline plc (GSK)
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 SANOFI S.A
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Pfizer Inc.
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 NOVARTIS AG
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Takeda Pharmaceuticals
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Astellas Pharma Inc.
8.3.7.1 Company Overview
8.3.7.2 Financial Performance
8.3.7.3 Product Benchmarking
8.3.7.4 Strategic Initiatives
8.3.8 Emergent BioSolutions
8.3.8.1 Company Overview
8.3.8.2 Financial Performance
8.3.8.3 Product Benchmarking
8.3.8.4 Strategic Initiatives
8.3.9 AstraZeneca
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Mitsubishi Tanabe
8.3.10.1 Company Overview
8.3.10.2 Financial Performance
8.3.10.3 Product Benchmarking
8.3.10.4 Strategic Initiatives
LIST OF TABLES
Table 1 North America Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 2 North America Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 3 U.S. Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 4 U.S. Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 5 Canada Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 6 Canada Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 7 Europe Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 8 Europe Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 9 Germany Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 10 Germany Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 11 UK Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 12 UK Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 13 Asia Pacific Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 14 Asia Pacific Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 15 China Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 16 China Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 17 Japan Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 18 Japan Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 19 Latin America Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 20 Latin America Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 21 Brazil Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 22 Brazil Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 23 MEA Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 24 MEA Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 25 South Africa Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 26 South Africa Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 1 North America Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 2 North America Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 3 U.S. Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 4 U.S. Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 5 Canada Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 6 Canada Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 7 Europe Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 8 Europe Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 9 Germany Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 10 Germany Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 11 UK Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 12 UK Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 13 Asia Pacific Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 14 Asia Pacific Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 15 China Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 16 China Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 17 Japan Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 18 Japan Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 19 Latin America Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 20 Latin America Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 21 Brazil Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 22 Brazil Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 23 MEA Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 24 MEA Vaccine Market, by application, 2013 - 2024 (USD Million)
Table 25 South Africa Vaccine Market, by type, 2013 - 2024 (USD Million)
Table 26 South Africa Vaccine Market, by application, 2013 - 2024 (USD Million)
